These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 2093529)

  • 1. Analysis of the factors in the cases resistant to recombinant human erythropoietin treatment.
    Suzuki M
    Contrib Nephrol; 1990; 82():65-71. PubMed ID: 2093529
    [No Abstract]   [Full Text] [Related]  

  • 2. [Utility of recombinant human erythropoietin on the anemia of elderly hemodialysis patients].
    Ueyama H; Nakahashi H; Sawanishi K; Kuze M; Ono T
    Hinyokika Kiyo; 1992 Dec; 38(12):1429-35. PubMed ID: 1288237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring erythropoietin therapy for anaemia of chronic renal failure by serum erythropoietin assays.
    Marsden JT; Sherwood RA; Hillis A; Peters TJ
    Ann Clin Biochem; 1993 Mar; 30 ( Pt 2)():205-6. PubMed ID: 8466156
    [No Abstract]   [Full Text] [Related]  

  • 4. Role of blood rheology in the pathogenesis of hypertension of hemodialysis patients treated for renal anemia with recombinant human erythropoietin.
    Baldamus CA; Steffen AM; Brunner R; Pollok M
    Contrib Nephrol; 1990; 82():79-85. PubMed ID: 2093531
    [No Abstract]   [Full Text] [Related]  

  • 5. Erythropoietin use in peritoneal dialysis patients.
    Zimmerman SW; Johnson CA
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):38-41. PubMed ID: 1928078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoietin treatment for anemia in end-stage renal disease with diabetes mellitus.
    Nakatsuka K; Hino M; Miki T; Nishizawa Y; Tabata T; Inoue T; Morii H
    Diabetes Care; 1990 Nov; 13(11):1130-1. PubMed ID: 2261828
    [No Abstract]   [Full Text] [Related]  

  • 7. Reasons for differences in dose requirements of recombinant human erythropoietin in haemodialysis patients.
    Scigalla P; Messinger D; Wieczorek L
    Contrib Nephrol; 1990; 82():55-64. PubMed ID: 2093527
    [No Abstract]   [Full Text] [Related]  

  • 8. Daily self-administered subcutaneous erythropoietin: benefits in haemodialysis patients.
    Granolleras C; Branger B; Deschodt G; Shaldon S; Nonnast-Daniel B; Pollok M
    Contrib Nephrol; 1990; 82():49-54. PubMed ID: 2093526
    [No Abstract]   [Full Text] [Related]  

  • 9. Erythropoietin.
    Haberl M
    Aust Nurses J; 1990 Sep; 20(2):29. PubMed ID: 2268202
    [No Abstract]   [Full Text] [Related]  

  • 10. Reticulocyte count used to assess recombinant human erythropoietin sensitivity in hemodialysis patients.
    Tatsumi N; Kojima K; Tsuda I; Yamagami S; Itoh Y; Tanaka H
    Contrib Nephrol; 1990; 82():41-8. PubMed ID: 2093525
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of anemia in chronically dialyzed patients].
    Moynot A
    Nephrologie; 1998; 19(3):125-7. PubMed ID: 9633055
    [No Abstract]   [Full Text] [Related]  

  • 12. Recombinant erythropoietin for the anemia of chronic renal failure.
    Ahmad R; Hand M
    N Engl J Med; 1987 Jul; 317(3):169-70. PubMed ID: 3600706
    [No Abstract]   [Full Text] [Related]  

  • 13. Erythropoietin for anemia of renal failure in sickle cell disease.
    Steinberg MH
    N Engl J Med; 1991 May; 324(19):1369-70. PubMed ID: 1759999
    [No Abstract]   [Full Text] [Related]  

  • 14. [Therapy of renal anemia with recombinant human erythropoietin].
    Schaefer RM; Kürner B; Zech M; Krahn R; Heidland A
    Dtsch Med Wochenschr; 1988 Jan; 113(4):125-9. PubMed ID: 3276487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The after effect of r-HuEPO in treating anemic hemodialysis patients].
    Chu JQ
    Zhonghua Hu Li Za Zhi; 1994 Feb; 29(2):78-9. PubMed ID: 7788758
    [No Abstract]   [Full Text] [Related]  

  • 16. [The recovery of erythropoiesis after the short-term Recormon treatment of renal anemia].
    Nikolaev AIu; Klepikov PV; Lashutin SV
    Ter Arkh; 1992; 64(6):90-1. PubMed ID: 1440349
    [No Abstract]   [Full Text] [Related]  

  • 17. [Recombinant human erythropoietin and chronic kidney failure: current situation and therapeutic implications].
    Romero González R; Torquet Escuder P
    Med Clin (Barc); 1990 Nov; 95(17):656-9. PubMed ID: 2089205
    [No Abstract]   [Full Text] [Related]  

  • 18. [Erythropoietin, blood viscosity and hypertension in chronic kidney failure].
    Schaefer RM; Heidland A
    Dtsch Med Wochenschr; 1989 Jun; 114(26):1046-9. PubMed ID: 2661190
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of recombinant human erythropoietin treatment in end-stage renal failure patients. Results of a multicenter phase II/III study.
    Pollok M; Bommer J; Gurland HJ; Koch KM; Schoeppe W; Scigalla P; Baldamus CA
    Contrib Nephrol; 1989; 76():201-11; discussion 212-8. PubMed ID: 2684523
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effect of recombinant human erythropoietin on hemodynamics in chronic hemodialysis patients].
    Tomura S
    Nihon Rinsho; 1991 Dec; 49 Suppl():695-701. PubMed ID: 1808338
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.